Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
dBET57 is a hybrid compound that drives the selective proteasomal degradation of bromodomain-containing protein 4 (BRD4).1 It is characterized as a proteolysis-targeting chimera (PROTAC) and contains JQ1, which binds bromo- and extra-terminal domain (BET) proteins, linked to thalidomide, a ligand for the E3 ubiquitin ligase cereblon. dBET57 is selective for inhibiting the interaction between cereblon and bromodomain 1 of BRD4 (BRD4BD1) over the interaction between cereblon and BRD4BD2 with apparent cooperativity factor α (αapp) values of 0.8 and less than 0.1, respectively, in an assay using purified bromodomains. It reduces BRD4BD1 protein levels in vitro with a half-maximal degradation (DC50) value of approximately 500 nM after five hours but does not reduce levels of BRD4BD2.
WARNING This product is not for human or veterinary use.
1. Plasticity in binding confers selectivity in ligand-